Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 65 full-time employees. The company went IPO on 2015-06-16. The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Follow-Up Questions
Healios KK のCEOは誰ですか？
Dr. Tadahisa Kagimoto は Healios KK の President で、2012 から在籍しています。
HLOSF の株価パフォーマンスは？
HLOSF の現在の価格は $3.5 で、最終取引日から 0% decreased 変動しました。
Healios KK の主な事業テーマや業界は？
Healios KK は Biotechnology 業界、セクターは Health Care に属しています。
